85 completed, 21 unknown, 13 terminated, 8 withdrawn. 36 Phase 1, 33 Phase 2, 32 Phase 3, 31 Phase 4, 10 Not applicable.
Follow this drug Literature Review of Oseltamivir trials Research Report on Oseltamivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD Xuanfei Jiangzhuo Decoction, Standard Antiviral Therapy (Oseltamivir or Baloxavir marboxil) - Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human | Not yet recruiting | Tianjin Medical University | 300 | 2026-08-01 | 2026-03-12 | |
| Post-exposure Influenza Prophylaxis in a Hospital Setting Oseltamivir - Influenza | Phase 3 | Active not recruiting | University Medical Centre Ljubljana | 200 | 2025-12-01 | 2026-04-30 |
| Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting Suraxavir marboxil, Oseltamivir Placebo, Oseltamivir - Influenza | Phase 3 | Recruiting | Capital Medical University | 384 | 2025-11-28 | 2026-03-23 |
| Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A ZSP1273, Oseltamivir - Influenza a | Phase 3 | Active not recruiting | Guangdong Raynovent Biotech Co., Ltd | 119 | 2025-11-22 | 2025-12-16 |
| Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza JKN2301 Dry Suspension, Oseltamivir Placebo, Oseltamivir - Respiratory Viral Infection | Phase 3 | Recruiting | Joincare Pharmaceutical Group Industry Co., Ltd | 177 | 2025-11-07 | 2026-01-21 |
| Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza ZX-7101A for oral suspension, Oseltamivir phosphate for oral suspension - Respiratory Viral Infection | Phase 3 | Completed | Nanjing Zenshine Pharmaceuticals | 169 | 2025-10-13 | 2026-04-16 |
| A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension Suraxavir Marboxil, Oseltamivir - Influenza | Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 144 | 2025-08-01 | 2025-08-08 |
| Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting Baloxavir Marboxil, Oseltamivir - Influenza, Influenza Prophylaxis | Not applicable | Not yet recruiting | Capital Medical University | 372 | 2025-01-05 | 2025-01-07 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms Baloxavir Marboxil, Oseltamivir - Influenza | Phase 3 | Completed | Hoffmann-La Roche | 100 | 2024-10-27 | 2026-04-27 |
| A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects ZX-7101A, Oseltamivir, ZX-7101A and Oseltamivir - Drug Interaction | Phase 1 | Completed | Nanjing Zenshine Pharmaceuticals | 18 | 2023-08-28 | 2024-11-04 |
| Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) Molnupiravir, Placebo molnupiravir, Placebo oseltamivir - Influenza Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 161 | 2023-08-21 | 2025-08-06 |
| Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza sirolimus and oseltamivir, Oseltamivir - Influenza | Phase 3 | Active not recruiting | Chinese University of Hong Kong | 160 | 2023-05-08 | 2026-10-20 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human | Phase 2 | Recruiting | University of Oxford | 3000 | 2023-02-22 | 2026-04-14 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers GP681, Rosuvastatin, Digoxin - Healthy Volunteers | Phase 1 | Completed | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 54 | 2023-02-15 | 2023-11-14 |
| Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza Baloxavir Marboxil, Placebo, Oseltamivir - Influenza | Phase 2 / Phase 3 | Terminated | Weill Medical College of Cornell University | 2 | 2022-04-22 | 2025-02-26 |
| Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients Baloxavir Marboxil, Oseltamivir - Hematopoietic and Lymphoid Cell Neoplasm, Influenza | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2021-10-11 | 2026-07-16 |
| Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product Oseltamivir 75mg Test Drug capsules, Oseltamivir 75mg capsules Reference Product capsules - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 36 | 2021-10-08 | 2021-10-28 |
| Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects HEC116094 - Influenza | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 118 | 2021-08-24 | 2023-04-12 |
| Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks Oseltamivir, Baloxavir - Influenza, Influenza, Human | Phase 4 | Unknown | Insight Therapeutics, LLC | 1000 | 2021-08-06 | 2023-03-15 |
| Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 standard treatment COVID-19 + Triazavirin - Covid19 | Phase 4 | Unknown | Ain Shams University | 80 | 2021-08-01 | 2021-07-22 |
Showing 20 of 140. Sign in to see all of them.
Influenza, Human (86) · COVID-19 (8) · Pneumonia (5) · Respiratory Tract Infections (5) · Virus Diseases (4) · Influenza in Birds (3) · Community-Acquired Pneumonia (2) · Heart Failure (2) · Hemorrhage (2) · Lung Diseases (2) · Orthomyxoviridae Infections (2) · Otitis Media (2) · Respiratory Tract Diseases (2) · Thrombocytopenia (2) · Adrenal Insufficiency (1)
Hoffmann-La Roche (19) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Capital Medical University (5) · GlaxoSmithKline (5) · University of Oxford (5) · Tongji Hospital (4) · Chinese University of Hong Kong (3) · MedImmune LLC (3) · The University of Hong Kong (3) · BioCryst Pharmaceuticals (2) · Genentech, Inc. (2) · Guangdong Raynovent Biotech Co., Ltd (2) · Hanmi Pharmaceutical Company Limited (2) · Janssen Research & Development, LLC (2) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (2)
United States (45) · China (29) · Canada (21) · Belgium (14) · France (14) · Spain (12) · Thailand (12) · South Africa (11) · United Kingdom (11) · Australia (10) · Germany (10) · Hong Kong (10) · Poland (10) · Italy (9) · New Zealand (9)
Bob Taylor, MD (2) · Chen Wang, Doctor (2) · Ji Young Park, MD, PhD (2) · John Beigel, MD (2) · Qingquan Liu, Docter (2) · Yu Mao, Doctor (2) · Adeep Puri (1) · Ahmed Elshafeey, Ph.D. Pharma (1) · Anand Kumar, MD (1) · Anil K Gupta, MD (1)
PMID 26042486, PMID 33394942, PMID 34473343, PMID 35585696, PMID 37489818, PMID 10628898, PMID 10934667, PMID 11744606, PMID 18074029, PMID 18559644, PMID 19005182, PMID 19637952, PMID 19846889, PMID 20815736, PMID 20936975, PMID 21072246, PMID 21106443, PMID 21406435, PMID 21844547, PMID 21930881, PMID 22264308, PMID 22520945, PMID 22728756, PMID 23111657, PMID 23208833, PMID 23230059, PMID 23264438, PMID 23697469, PMID 23723457, PMID 24046309, PMID 24268590, PMID 24366750, PMID 25213733, PMID 25289522, PMID 25788164, PMID 25849228, PMID 25873046, PMID 26015411, PMID 27616034, PMID 28094141, PMID 28437488, PMID 28464462, PMID 28583578, PMID 28639229, PMID 28698321, PMID 28807912, PMID 28880856, PMID 28958678, PMID 29077848, PMID 29659754
2016 (4), 2014 (3), 2008 (2), 2009 (2), 2015 (2), 2018 (1), 2023 (1), N01AI30025 (1), N01AO50042 (1), U01IP000127 (1), U10HD047905 (1)